Rheumatology International

, Volume 26, Issue 4, pp 288–291

Early effect of nasal salmon calcitonin on the bone marker Crosslaps

  • Demet Ofluoglu
  • Evrim Karadag-Saygi
  • Cuneyt Canbulat
  • Osman Hakan Gunduz
  • Evren KUL-Panza
  • Gulseren Akyuz
Original Article

Abstract

The aim of this study was to investigate the early effect of nasal salmon calcitonin on a bone-resorption marker, “Crosslaps”, in postmenopausal osteoporotic women. In this randomized, single-blind and placebo-controlled study we included 78 postmenopausal women with osteoporosis, between 45 and 65 years of age, with at least 5 years duration of menopause. Patients were randomly divided into two groups, the treatment and the placebo groups. Patients in the treatment group were given 100 IU day−1 nasal salmon calcitonin, 1,000 mg day−1 elemental calcium, and 400 IU day−1 vitamin D. Patients in the placebo group took only 1,000 mg day−1 elemental calcium, and 400 IU day−1 vitamin D. The outcome measurements were urinary deoxypyridinoline, serum alkaline phosphatase, osteocalcin, and Crosslaps. The treatment group consisted of 39 patients whose mean age was 60.4±6 years and the placebo group included 39 patients with a mean age of 60.5±4.9 years. There was no significant difference between two groups in terms of demographic characteristics. The results of bone marker measurements were analyzed statistically. Crosslaps levels in the treatment group were significantly lower (P<0.05) than in the placebo group. Other bone marker levels at the end of the study were not significantly lower (P>0.05) than those at baseline in both treatment and placebo groups, however. Salmon calcitonin affects bone turnover within a few months and bone-resorption markers such as Crosslaps can be used to monitor the effect of nasal salmon calcitonin in the early phase of treatment for postmenopausal osteoporosis.

Keywords

Osteoporosis Calcitonin Bone markers Crosslaps 

References

  1. 1.
    Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, Nordin BE, Barrett-Connor E, Black D, Bonjour JP, Dawson-Hughes B, Delmas PD, Dequeker J, Ragi Eis S, Gennari C, Johnell O, Johnston CC Jr, Lau EM, Liberman UA, Lindsay R, Martin TJ, Masri B, Mautalen CA, Meunier PJ, Khaltaev N et al (1999) Interim report and recommendation of the World Health Organization Task-force for the osteoporosis. Osteoporos Int 10:259–264CrossRefPubMedGoogle Scholar
  2. 2.
    Weiss M, Ben-Shlomo AB, Hagag P, Rapoport M (2000) Reference database for bone speed of sound measurement by novel quantitative multi-site ultrasound device. Osteoporos Int 11:688–696CrossRefPubMedGoogle Scholar
  3. 3.
    Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 7:390–406CrossRefPubMedGoogle Scholar
  4. 4.
    Brown JP, Josse RG (2002) for the Scientific Advisory Council of the Osteoporosis Society of Canada 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 12(167)(10 Suppl):S1–S34Google Scholar
  5. 5.
    Wahner HW (1996) Use of Densitometry in Management of Osteoporosis. In: Marcus R, Feldmen D, Kelsey J (eds) Osteoporosis. Academic, California, pp 1055–1072Google Scholar
  6. 6.
    Tannirandorn P, Epstein S (2000) Drug-induced bone loss. Osteoporos Int 11:637–659CrossRefPubMedGoogle Scholar
  7. 7.
    Mehta NM, Malootian A, Gilligan JP (2003) Calcitonin for osteoporosis and bone pain. Curr Pharm Des 9(32):2659–2676CrossRefPubMedGoogle Scholar
  8. 8.
    Halkin V, Reginster JV (1998) Efficacy and tolerability of calcitonin in the treatment and prevention of osteoporosis. Biodrugs 10(4):295–300Google Scholar
  9. 9.
    Delmas PD, Eastell R, Garnero P, Seibel MJ and Stepan J (2000) for the Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int Suppl 6:S2–S17CrossRefGoogle Scholar
  10. 10.
    Garnero P, Borel O, Delmas P (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type 1 collagen in osteoporosis. Clin Chem 47(4):694–702PubMedGoogle Scholar
  11. 11.
    Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantlou E (2002) A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 17(3):521–527PubMedGoogle Scholar
  12. 12.
    Overgoard K, Christiansen C (1999) A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin. Calcif Tissue Int 59:12–16CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Demet Ofluoglu
    • 1
  • Evrim Karadag-Saygi
    • 1
  • Cuneyt Canbulat
    • 2
  • Osman Hakan Gunduz
    • 1
  • Evren KUL-Panza
    • 1
  • Gulseren Akyuz
    • 1
  1. 1.Physical Medicine and Rehabilitation DepartmentMarmara University School of MedicineAltunizade, IstanbulTurkey
  2. 2.Biochemistry DepartmentPTT HospitalIstanbulTurkey

Personalised recommendations